Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 2011

View Archived Issues

iBioLaunch platform expresses protein to be studied as vaccine against hookworm disease

NicOx's NCX-226 reduces symptoms of inflammation in murine model of lung fibrosis

Olanzapine oral and LAI formulations show similar effectiveness in schizophrenia

R1-1084 and R1-770 well tolerated by patients with metastatic renal cell carcinoma

RLY-5016 dose titration avoids hypokalemia in patients with heart failure and kidney disease

Intedanib has beneficial effects in TOMORROW trial in idiopathic pulmonary fibrosis

Scientists at GSK design new P2X7 receptor antagonists

Novel cyclic dipeptides for neurodegenerative diseases presented

New diacylglycerol O-acyltransferase 1 inhibitors patented

GSK claims new inhibitors of serine/threonine-protein kinase TNNI3K

Novel bromodomain-containing protein inhibitors disclosed

InterMune reports new NS5B inhibitors for hepatitis C

Nationwide Children's Hospital receives NIH grant to advance gene therapy for MPS IIIB

Initiation of phase I trial in pain triggers milestone payment to Evotec from Boehringer Ingelheim

First patient enrolled in high-dose cohort of phase II SHIGATEC trial

European Commission approves extended use of Carbaglu for organic acidemias

Dyax and Defiante Farmaceutica expand agreement for ecallantide in HAE

Cleveland BioLabs and BARDA advance negotiations relating to development of CBLB-502

Affymax and Takeda submit NDA for peginesatide in anemia associated with chronic renal failure

GenKyoTex raises funds to develop NADPH oxidase inhibitors

Nuron Biotech to use PolyTherics' TheraPEG technology for long-acting MS therapy

BioSante completes enrollment in phase III safety study of LibiGel

Capstone Therapeutics and BiolineRx sign agreement for development of Chrysalin in AMI

Diamyd Medical stops follow-up in European phase III study of Diamyd in diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...